Core Viewpoint - Generate Biomedicines, Inc. has announced the pricing of its initial public offering (IPO) at $16.00 per share, aiming to raise gross proceeds of $400 million before expenses [1] Group 1: IPO Details - The company is offering 25,000,000 shares of common stock in the IPO [1] - Underwriters have a 30-day option to purchase an additional 3,750,000 shares at the IPO price [1] - Trading on the Nasdaq Global Select Market is expected to commence on February 27, 2026, under the ticker symbol "GENB" [1] Group 2: Financial Management - Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint lead book-running managers for the offering [1] - Other book-running managers include Piper Sandler, Guggenheim Securities, and Cantor [1] Group 3: Regulatory Information - A registration statement for the securities was filed and declared effective by the U.S. Securities and Exchange Commission on February 26, 2026 [1] - The offering is being conducted solely through a prospectus [1]

As filed with the Securities and Exchange Commission on February 23, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 9 ...

As filed with the Securities and Exchange Commission on February 4, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (8 ...